0.58
price up icon1.72%   0.0098
after-market After Hours: .58
loading
Novabay Pharmaceuticals Inc stock is traded at $0.58, with a volume of 12,273. It is up +1.72% in the last 24 hours and down -4.92% over the past month. NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets non-antibiotic and anti-infective products for the eye care market in the United States, China, and internationally. It offers Avenova, a prescription product for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye; NeutroPhase for wound care market; CelleRx for the aesthetic dermatology market; Aganocide compounds patented synthetic molecules for use against bacteria, viruses, and fungi; auriclosene irrigation solution for urology; and intelli-Case, a device for soft and rigid gas permeable contact lenses. NovaBay Pharmaceuticals, Inc. has collaboration and license agreement with Virbac to develop auriclosene, a proprietary compound for veterinary markets. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is based in Emeryville, California.
See More
Previous Close:
$0.5702
Open:
$0.5702
24h Volume:
12,273
Relative Volume:
0.14
Market Cap:
$3.49M
Revenue:
$14.64M
Net Income/Loss:
$-13.74M
P/E Ratio:
-0.0798
EPS:
-7.27
Net Cash Flow:
$-5.04M
1W Performance:
-3.33%
1M Performance:
-4.92%
6M Performance:
+5.26%
1Y Performance:
-78.48%
1-Day Range:
Value
$0.5702
$0.5872
1-Week Range:
Value
$0.5601
$0.61
52-Week Range:
Value
$0.3611
$9.079

Novabay Pharmaceuticals Inc Stock (NBY) Company Profile

Name
Name
Novabay Pharmaceuticals Inc
Name
Phone
510-899-8800
Name
Address
2000 Powell Street, Suite 1150, Emeryville, CA
Name
Employee
86
Name
Twitter
@NovaBayPharma
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
NBY's Discussions on Twitter

Compare NBY with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
NBY
Novabay Pharmaceuticals Inc
0.58 3.49M 14.64M -13.74M -5.04M -7.27
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
493.84 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
602.64 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
614.76 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.56 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
244.90 24.70B 3.81B -644.79M -669.77M -6.24

Novabay Pharmaceuticals Inc Stock (NBY) Upgrades & Downgrades

Date Action Analyst Rating Change
Sep-18-19 Initiated Ladenburg Thalmann Buy
Jul-06-18 Reiterated H.C. Wainwright Buy
Nov-15-17 Reiterated Laidlaw Buy
Jun-05-17 Initiated ROTH Capital Buy
Mar-27-17 Initiated Laidlaw Buy
Feb-06-17 Initiated Rodman & Renshaw Buy
Mar-07-16 Downgrade Maxim Group Buy → Hold
Dec-14-15 Reiterated Maxim Group Buy
Apr-30-15 Resumed Maxim Group Buy
Mar-06-13 Initiated Ascendiant Capital Markets Strong Buy
Jan-03-08 Initiated Dawson James Speculative Buy
View All

Novabay Pharmaceuticals Inc Stock (NBY) Latest News

pulisher
Apr 26, 2025

NovaBay Pharmaceuticals (NYSE:NBY) Now Covered by Analysts at StockNews.com - Defense World

Apr 26, 2025
pulisher
Apr 25, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 25, 2025
pulisher
Apr 22, 2025

NovaBay Pharmaceuticals approves liquidation plan By Investing.com - Investing.com Canada

Apr 22, 2025
pulisher
Apr 22, 2025

NovaBay Pharmaceuticals approves liquidation plan - Investing.com

Apr 22, 2025
pulisher
Apr 16, 2025

Poplar Point Capital Partners acquires $39,503 in NovaBay shares - Investing.com Australia

Apr 16, 2025
pulisher
Apr 16, 2025

Poplar Point Capital Partners increases stake in NovaBay Pharmaceuticals By Investing.com - Investing.com South Africa

Apr 16, 2025
pulisher
Apr 15, 2025

Massive Stock Acquisition: Poplar Point Capital Partners Bets Big on NovaBay Pharma! - TipRanks

Apr 15, 2025
pulisher
Apr 15, 2025

Poplar Point Capital Partners acquires $29,857 in NovaBay shares - Investing.com Australia

Apr 15, 2025
pulisher
Apr 15, 2025

Poplar Point Capital increases stake in NovaBay Pharmaceuticals By Investing.com - Investing.com India

Apr 15, 2025
pulisher
Apr 15, 2025

Poplar Point Capital Partners acquires $39,503 in NovaBay shares By Investing.com - Investing.com India

Apr 15, 2025
pulisher
Apr 15, 2025

Poplar Point Capital Partners acquires $29,857 in NovaBay shares By Investing.com - Investing.com Canada

Apr 15, 2025
pulisher
Apr 15, 2025

Novabay Pharmaceuticals sees $15,966 in recent stock acquisitions - Investing.com

Apr 15, 2025
pulisher
Apr 15, 2025

Novabay Pharmaceuticals sees $15,966 in recent stock acquisitions By Investing.com - Investing.com UK

Apr 15, 2025
pulisher
Apr 15, 2025

Poplar Point Capital increases stake in NovaBay Pharmaceuticals - Investing.com

Apr 15, 2025
pulisher
Apr 15, 2025

NovaBay Pharmaceuticals sees $67,700 stock acquisition by Poplar Point Capital - Investing.com India

Apr 15, 2025
pulisher
Apr 02, 2025

NovaBay Pharmaceuticals Inc. (NBY) reports earnings - qz.com

Apr 02, 2025
pulisher
Apr 01, 2025

NovaBay Pharmaceuticals Delays Yearly Report Filing - TipRanks

Apr 01, 2025
pulisher
Mar 28, 2025

CNS Pharma Stock Price, Quotes and Forecasts | NASDAQ:CNSP - Benzinga

Mar 28, 2025
pulisher
Mar 27, 2025

Revolutionizing Healing: Trends in the Advanced Wound Care Market with NovaBay, Healthy.io - openPR.com

Mar 27, 2025
pulisher
Mar 24, 2025

Blepharitis Treatment Market Future Business Opportunities - openPR.com

Mar 24, 2025
pulisher
Mar 18, 2025

NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) Sees Significant Decrease in Short Interest - Defense World

Mar 18, 2025
pulisher
Mar 18, 2025

NovaBay Pharmaceuticals (NBY) Projected to Post Quarterly Earnings on Tuesday - Defense World

Mar 18, 2025
pulisher
Mar 12, 2025

NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Share Price Passes Above 50-Day Moving Average – Time to Sell? - Defense World

Mar 12, 2025
pulisher
Mar 12, 2025

NovaBay reaches settlements over disputed warrants By Investing.com - Investing.com Australia

Mar 12, 2025
pulisher
Mar 11, 2025

NovaBay reaches settlements over disputed warrants - Investing.com India

Mar 11, 2025
pulisher
Mar 08, 2025

NovaBay Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire

Mar 08, 2025
pulisher
Mar 07, 2025

Novabay Pharmaceuticals Engages Financial Advisor Should Stockholders Fail To Approve Dissolution Proposal - Marketscreener.com

Mar 07, 2025
pulisher
Mar 07, 2025

NovaBay Pharmaceuticals to Hold Special Meeting of Stockholders - Business Wire

Mar 07, 2025
pulisher
Mar 06, 2025

NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) Short Interest Update - Defense World

Mar 06, 2025
pulisher
Mar 01, 2025

StockNews.com Initiates Coverage on NovaBay Pharmaceuticals (NYSE:NBY) - Defense World

Mar 01, 2025
pulisher
Feb 27, 2025

Investor Network: NovaBay Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 27, 2025

NovaBay's Avenova Highlighted in National Dry Eye Awareness Month - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 21, 2025

NovaBay Pharmaceuticals (NYSE:NBY) Earns Hold Rating from Analysts at StockNews.com - Defense World

Feb 21, 2025
pulisher
Feb 17, 2025

NovaBay extends CEO's contract through 2025 - MSN

Feb 17, 2025
pulisher
Feb 13, 2025

StockNews.com Begins Coverage on NovaBay Pharmaceuticals (NYSE:NBY) - Defense World

Feb 13, 2025
pulisher
Feb 08, 2025

NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Stock Price Crosses Above Fifty Day Moving Average – Time to Sell? - Armenian Reporter

Feb 08, 2025
pulisher
Feb 06, 2025

NovaBay fails to gain shareholder approval for dissolution - MSN

Feb 06, 2025
pulisher
Feb 04, 2025

NovaBay fails to gain shareholder approval for dissolution By Investing.com - Investing.com Canada

Feb 04, 2025
pulisher
Jan 28, 2025

NovaBay Pharmaceuticals (NYSE:NBY) Coverage Initiated at StockNews.com - Defense World

Jan 28, 2025
pulisher
Jan 25, 2025

**NovaBay Pharmaceuticals Completes Asset Sale Transaction and Plans for Dissolution**** - Defense World

Jan 25, 2025
pulisher
Jan 24, 2025

NovaBay Pharmaceuticals Completes the Sale of its Avenova Eyecare Business to PRN, Seeks Full Company Dissolution - Vision Monday

Jan 24, 2025
pulisher
Jan 23, 2025

NovaBay Pharma’s Strategic Shift and Liquidation Plans - TipRanks

Jan 23, 2025

Novabay Pharmaceuticals Inc Stock (NBY) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.59
price up icon 0.24%
$69.69
price up icon 1.06%
$32.20
price up icon 0.53%
$23.46
price down icon 36.06%
$102.02
price down icon 15.36%
biotechnology ONC
$244.90
price down icon 4.40%
Cap:     |  Volume (24h):